PACIRA BIOSCIENCES, INC. Operating Lease Liability
PACIRA BIOSCIENCES, INC. (PCRX) had Operating Lease Liability of $48.99 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-04
- 2026-06-30: Operating Lease, Liability $48.99M.
- 2026-03-31: Operating Lease, Liability $43.52M.
- 2025-12-31: Operating Lease, Liability $46.02M.
- 2025-09-30: Operating Lease, Liability $48.59M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $48.99M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $43.52M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $46.02M 10-K · filed 2026-02-26 |
| 2025-09-30 | $48.59M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.91M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $53.08M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $53.53M 10-K · filed 2025-02-27 |
| 2024-09-30 | $57.07M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $59.30M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $61.45M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $63.61M 10-K · filed 2024-02-29 |
| 2023-09-30 | $65.71M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $69.03M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $71.39M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $73.92M 10-K · filed 2023-02-28 |
| 2022-09-30 | $73.77M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $75.71M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $77.73M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $79.62M 10-K · filed 2022-02-28 |
| 2021-09-30 | $72.66M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $73.88M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $75.17M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $78.45M 10-K · filed 2021-03-01 |
| 2020-09-30 | $79.90M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $81.51M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $44.16M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $45.87M 10-K · filed 2020-02-21 |
| 2019-09-30 | $43.92M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $45.21M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $34.88M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |